# Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled Budesonide in COPD Patients

> **NCT00483743** · PHASE2 · COMPLETED · sponsor: **Syntara** · enrollment: 62 (actual)

## Conditions studied

- Copd Bronchitis

## Interventions

- **DRUG:** TPI 1020
- **DRUG:** Budesonide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00483743
- **Lead sponsor:** Syntara
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2012-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00483743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00483743, "Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled Budesonide in COPD Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00483743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*